For 25 years, Morunda has been interviewing leaders in Japan’s pharmaceutical and medical device industry. Most country managers typically come from a commercial background, rooted in sales and marketing. It’s rare to find country managers who come from finance or…
HOME > BUSINESS
BUSINESS
- Biogen/Eisai Alzheimer’s Pact Amended to Switch Aducanumab Collab to Royalty Scheme
March 16, 2022
- Astellas’ Vasomotor Symptom Med Missed Primary Goal in Asian PIII Study
March 16, 2022
- AbbVie Seeks Japan Approval of Advanced Parkinson’s Med, New Indication for Rinvoq
March 15, 2022
- Mitsubishi Tanabe’s Oral Edaravone Filed in Japan for ALS
March 15, 2022
- ViiV Submits Long-Acting Cabotegravir Injectable for HIV in Japan
March 14, 2022
- Nubeqa Filed for Metastatic Prostate Cancer in Japan: Bayer
March 14, 2022
- Moderna Accelerating Bivalent Vaccine Development for 4th COVID Shot: Japan Chief
March 14, 2022
- Fujifilm Drops Avigan’s Japan PIII Trial for COVID-19
March 14, 2022
- Shionogi, XNef, ATR Join Hands on R&D for Diagnosis/Stratified Markers of Neuropsychiatric Disorders
March 14, 2022
- Sumitomo Dainippon Invests an Additional 200 Million Yen into Aikomi
March 14, 2022
- Toho Gets 20% Stake in Ayumi’s Holdings Firm, Eyes RA Biosimilar Market
March 11, 2022
- Authorized Generics Likely Speeding Up G1/G2 Price Cuts for Off-Patent Brands: Jiho Tally
March 11, 2022
- Chugai Won’t Challenge Edirol Substance Patent Ruling
March 11, 2022
- Toa Eiyo Kickstarts Japan PIIb/III for Sakigake Designated TGCV Med
March 11, 2022
- Japan Drug Makers Moving to Support War-Hit Ukraine
March 10, 2022
- Opdivo Tops Japan Sales Ranking in February: Encise
March 10, 2022
- Astellas to Submit Improvement Plans for Gene Therapy Trial by September over Patient Deaths
March 10, 2022
- Double-Digit Slashes to Hit 44 Major Drugs in 2022 Price Revision: Top 5 Product Poll
March 9, 2022
- Rakuten Medical’s Photoimmunotherapy Platform Renamed Alluminox
March 9, 2022
- Nobelpharma, Toyo Ink Tie Up on Biologics Development, Overseas Expansion
March 9, 2022
ページ
Earlier this month, the Ministry of Finance (MOF) unveiled a long list of social security proposals towards the FY2025 budgeting,…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…